Those proteins included HIF1α, HIF2α and their target genes c-Myc and β-catenin, as well as MXI1 and MCL-1 that are closely associated with c-Myc, EMT markers and effectors of the Akt signaling pathway that are potentially associated with tumor response to sorafenib treatment. The gene discussed is MCL1; the disease is neoplasm.